Importance of implant dosimetry for patients undergoing prostate brachytherapy

Urology

Volumn 62, Issue 6, 2003, Pages 1073-1077

  Potters, Louis ^a   Huang, David ^b   Calugaru, Emel ^b   Fearn, Paul ^b   Lee, Lucille ^b   Kattan, Michael W ^b  

^a SOUTH NASSAU COMMUNITIES HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; EVALUATION; FOLLOW UP; HORMONAL THERAPY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE;

EID: 0344234456     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.07.004     Document Type: Article

References (22)

1. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate techniques, patient selection, and clinical outcomes . Semin Radiat Oncol. 12:2002;81-94.
2. Potters L., Fearn P., Kattan M.W. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy. 1:2002;36-41.
3. Fleming I., Cooper J.S., Henson D.E., et al. AJCC Cancer Staging Manual. 5th ed :1997;Lippincott-Raven, Philadelphia.
4. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:1999;789-799.
5. Beyer D., Nath R., Butler W., et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. Int J Radiat Oncol Biol Phys. 47:2000;273-275.
6. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 . (published erratum appears in Med Phys 23: 1579, 1996) Med Phys. 22:1995;209-234.
7. Consensus statement guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
8. Kattan M.W., Fearn P.A., Leibel S., et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 48:2000;1469-1474.
9. Cox D.R., Abadir R. Regression models and life tables. J Roy Stat Soc. 34:1972;187-220.
10. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol. 53:1958;457-516.
11. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
12. Ragde H., Grado G.L., Nadir B.S. Brachytherapy for clinically localized prostate cancer thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone . Arch Esp Urol. 54:2001;739-747.
13. Anderson L.L. Plan optimization and dose evaluation in brachytherapy. Semin Radiat Oncol. 3:1993;290-300.
14. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
15. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 50:2001;605-614.
16. D'Amico A., Cormack R., Kumar S., et al. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol. 14:2000;367-370.
17. Nag S., Bice W.S., DeWyngaert J.K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 46:2000;221-230.
18. Sylvester J., Blasko J.C., Grimm P.D., et al. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer a matched subset analysis . Mol Urol. 4:2000;155-161.
19. Lee H.H., Warde P., Jewett M.A. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int. 83:1999;438-448.
20. Hanks G.E. Strategies for improving the outcome of patients with poor prognosis prostate cancers. Acta Oncol. 37:1998;5-9.
21. Roach M. III, Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy a meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys. 47:2000;617-627.
22. Stone N., Hong S., Lo Y.C., et al. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy. 2:2003;17-25.